These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9808688)

  • 1. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat.
    Proksch JW; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 1998 Nov; 287(2):616-24. PubMed ID: 9808688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
    Valentine JL; Owens SM
    J Pharmacol Exp Ther; 1996 Aug; 278(2):717-24. PubMed ID: 8768723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats.
    McClurkan MB; Valentine JL; Arnold L; Owens SM
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1439-45. PubMed ID: 8371148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats.
    Valentine JL; Arnold LW; Owens SM
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1079-85. PubMed ID: 8014850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.
    Proksch JW; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 2000 Mar; 292(3):831-7. PubMed ID: 10688594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs.
    Owens SM; Mayersohn M
    Drug Metab Dispos; 1986; 14(1):52-8. PubMed ID: 2868866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
    Valentine JL; Mayersohn M; Wessinger WD; Arnold LW; Owens SM
    J Pharmacol Exp Ther; 1996 Aug; 278(2):709-16. PubMed ID: 8768722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
    Hardin JS; Wessinger WD; Proksch JW; Owens SM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1113-22. PubMed ID: 9618414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted.
    Pitas G; Laurenzana EM; Williams DK; Owens SM; Gentry WB
    Drug Metab Dispos; 2006 Jun; 34(6):906-12. PubMed ID: 16507651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum.
    Proksch JW; Gentry WB; Owens SM
    Drug Metab Dispos; 2000 Jul; 28(7):742-7. PubMed ID: 10859146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phencyclidine dependence: the relationship of dose and serum concentrations to operant behavioral effects.
    Wessinger WD; Owens SM
    J Pharmacol Exp Ther; 1991 Jul; 258(1):207-15. PubMed ID: 2072296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of [3H]1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) in Sprague-Dawley rats.
    Zorbas M; Owens SM; Plunkett LM; Bui H
    Drug Metab Dispos; 1989; 17(6):641-5. PubMed ID: 2575500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.
    Woodworth JR; Owens SM; Mayersohn M
    J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody.
    Laurenzana EM; Gunnell MG; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1092-8. PubMed ID: 12829731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.
    Kalinichev M; Robbins MJ; Hartfield EM; Maycox PR; Moore SH; Savage KM; Austin NE; Jones DN
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):414-22. PubMed ID: 17945407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and toxicity of high doses of antibody Fab fragments in rats.
    Pentel PR; Keyler DE; Gilbertson DG; Ruth G; Pond SM
    Drug Metab Dispos; 1988; 16(1):141-5. PubMed ID: 2894943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific Fab fragments.
    Owens SM; Mayersohn M
    NIDA Res Monogr; 1986; 64():112-26. PubMed ID: 3086729
    [No Abstract]   [Full Text] [Related]  

  • 20. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats.
    Hardin JS; Wessinger WD; Wenger GR; Proksch JW; Laurenzana EM; Owens SM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):119-26. PubMed ID: 12065708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.